Woolley Pau wins Novo Nordisk insulin accounts
pharmafile | April 26, 2005 | News story | Medical Communications |
Following a four-way pitch, Convent Garden-based advertising agency Woolley Pau has been appointed by Novo Nordisk to work on its three main insulin analogue brands.
The agency was picked to work on Novo Nordisk's Levemir, NovoRapid and NovoMix and will handle all the advertising and promotional work for a new campaign for the products.
Jean Woodward, marketing manager at Novo Nordisk, commented: "We liked Woolley Pau's approach to the pitch and their obvious enthusiasm. It was a true team effort and their enthusiasm shone through."
Woolley Pau's appointment marks two firsts for the agency: their first diabetes account win and their first time working with Novo Nordisk, although Woolley Pau account director Helen Dell previously worked with the pharma company whilst at her previous agency, Matthew Poppy Ogilvy.
Helen said: "This is an exciting opportunity for us and we look forward to working closely with the Novo Nordisk marketing team to create a memorable campaign."
Woolley Pau will have to bear in mind some recent changes to the products' licences in its work for Novo Nordisk as the pharma company recently received European Commission approval for new paediatric indications for Levemir and NovoRapid.
The licence for the long-acting analogue Levemir has been extended to include the treatment of diabetes in children and adolescents aged six to 17 years old. It first received European approval in June 2004 for the treatment of diabetes in adults.
Novo Nordisk's fast-acting treatment NovoRapid also received an extended authorisation from the Commission, which now sees its licence include the treatment of diabetes in children aged two to six years old.
Meanwhile, Novo Nordisk's future plans for its dual-release insulin analogue, NovoMix, include producing it in two additional premixed formulations, adding to an insulin portfolio that is the most complete in the industry.
"With these new premixed formulations, premixed insulins become an even more attractive treatment option for people with type I and II diabetes," the company said.
